财报披露
Can-fite Biopharma(CANF)07-01 19:15
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-057535 Act: 34 Size: 42 KB 网页链接
简介:Can-fite Biopharma Ltd.创建于1994年9月11日,该公司是一家临床阶段的生物制药公司,专注于研发治疗自身免疫性炎症,肿瘤和眼科疾病的口服生物小分子治疗产品。该平台技术利用Gi蛋白相关的A 3 AR作为治疗靶标。A 3 AR高度表现在炎性细胞和癌细胞上,但在正常细胞中没有显著表现,这表明该受体可以作为药物介入的独特目标。该管道药物是人工合成的,属于高度特定的受体激动剂和变构调节剂,配体或分子,而这些分子在将A 3 AR作靶,并与靶蛋白结合时,发起了分子事件。
今开:2.49 | 昨收:2.42 |
最高:2.5399 | 最低:2.42 |
涨停价: | 跌停价: |
总市值:12476070 |
Can-fite Biopharma(CANF)07-01 19:15
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-057535 Act: 34 Size: 42 KB 网页链接
Can-fite Biopharma(CANF)06-28 19:05
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056848 Act: 34 Size: 25 KB 网页链接
Can-fite Biopharma(CANF)06-24 19:15
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-054980 Act: 34 Size: 22 KB 网页链接
Can-fite Biopharma(CANF)05-06 19:15
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-039894 Act: 34 Size: 24 KB 网页链接
Can-fite Biopharma(CANF)04-15 19:05
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-032722 Act: 34 Size: 203 KB 网页链接
Can-fite Biopharma(CANF)05-29 19:35
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-047244 Act: 34 Size: 20 KB 网页链接
Can-fite Biopharma(CANF)06-29 04:25
$Can-fite Biopharma(CANF)$ 424B7 Prospectus [Rule 424(b)(7)] Accession Number: 0001213900-24-057194 Act: 33 Size: 42 KB 网页链接
Can-fite Biopharma(CANF)07-04 01:25
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-058931 Act: 34 Size: 10 KB 网页链接
Can-fite Biopharma(CANF)04-25 19:05
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-035955 Act: 34 Size: 21 KB 网页链接
Can-fite Biopharma(CANF)05-09 19:05
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-041020 Act: 34 Size: 24 KB 网页链接
君2O2022-03-24 23:51
$灿菲特生物制药(CANF)$ 新冠要搞出来了。查看全文
chuminhua2021-12-21 17:53
12月20日, Can-Fite宣布,在Namodenoson治疗肝细胞癌 (HCC)的II期研究的开放标签扩展试验部分,接受治疗的最后一名患者获得了完全缓解 (CR) ,这意味着这名患者的所有癌症病灶全部清除。在接受namodenson治疗后,患者已经存活了5年,在此期间治疗的临床益处包括腹水消失、肝功能正常以及腹腔内散...查看全文
TCLDBY2021-11-16 00:22
$灿菲特生物制药(CANF)$ 睡醒了?查看全文
鲜克有终72021-09-03 01:39
TCLDBY2021-06-29 23:04
$灿菲特生物制药(CANF)$ 该反攻了吧查看全文
牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
KarolChiu2021-03-18 18:11
$灿菲特生物制药(CANF)$ 一日行情查看全文
枫林居士2021-03-16 22:23
$灿菲特生物制药(CANF)$开盘的时候最牛的是你,最具操作价值的却是$SunLink卫生系统(SSY)$查看全文
枫林居士2021-03-16 22:06
$灿菲特生物制药(CANF)$ 跌到3块才能抄底?查看全文
HySgpr2021-02-13 03:28
$灿菲特生物制药(CANF)$ 继续加,等爆查看全文
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-058931 Act: 34 Size: 10 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-057535 Act: 34 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 424B7 Prospectus [Rule 424(b)(7)] Accession Number: 0001213900-24-057194 Act: 33 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056848 Act: 34 Size: 25 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056177 Act: 34 Size: 9 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-054980 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050960 Act: 34 Size: 26 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050777 Act: 34 Size: 1 MB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-049861 Act: 34 Size: 20 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-047244 Act: 34 Size: 20 KB 网页链接